 CAMBRIDGE, Mass.-- BUSINESS WIRE --Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection rCDI on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration. 